NEWS
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Lipella Pharmaceuticals (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry to advance research and treatment development for this chronic inflammatory disease affecting approximately 6 million Americans. OLP, which impacts the mouth's mucous membranes, currently has no FDA-approved therapies.
The company is also conducting an investigational study of LP-310, an oral rinse derived from their lead candidate LP-10. LP-310 has received FDA approval for clinical evaluation in treating OLP. This initiative aligns with Lipella's mission to improve treatment approaches for OLP, a condition characterized by burning pain, white patches, swollen tissue, and open sores.
The company is also conducting an investigational study of LP-310, an oral rinse derived from their lead candidate LP-10. LP-310 has received FDA approval for clinical evaluation in treating OLP. This initiative aligns with Lipella's mission to improve treatment approaches for OLP, a condition characterized by burning pain, white patches, swollen tissue, and open sores.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1633Followers
89Following
12KVisitors
Follow
Uptrendpls : Looks good for the news right.
Jaguar8 OP Uptrendpls : Good news but we shall see buy side if it gets much attention today plus shorts of course
Uptrendpls Jaguar8 OP : Thanks bro